Controversies in the Management of AML in Older Patients: A Canadian Perspective.

Andre C Schuh, Joseph Brandwein, Mahmoud Elsawy, David Sanford, Brian Leber

Abstract readReview

In one paragraph

Review in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Charting the Future of Canadian Adult Acute Myeloid Leukemia (AML) Laboratory Testing: A Canadian Leukemia Study Group Current State Mapping of Diagnostic AML Laboratory Practice.Current oncology (Toronto, Ont.) · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andre C SchuhDepartments of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.

Joseph BrandweinDivision of Hematology, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada.ORCID 0000-0001-9095-8789

Mahmoud ElsawyDivision of Hematology and Hematologic Oncology, Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada.

David SanfordDivision of Hematology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.

Brian LeberDepartment of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada.ORCID 0000-0001-5502-1480

Funding

CLSG/GCEL received unrestricted funding from AbbVie, Amgen Canada, Astellas Pharma Can-ada, BMS Canada, Jazz Pharma Canada, Novartis Canada, Pfizer Canada, Servier Canada and Taiho Canada.

6 · The paper itself

Abstract

In the companion article in this issue of

Indexed as

Leukemia, Myeloid, AcuteAgedCanadafms-Like Tyrosine Kinase 3HumansIsocitrate DehydrogenaseMutationNucleophosminfms-Like Tyrosine Kinase 3Isocitrate DehydrogenaseNPM1 protein, humanNucleophosminacute myeloid leukemiaelderly patientsgenetically defined riskless-intensive treatmentrisk stratification

Identifiers

PMID42505233

DOI10.3390/curroncol33070431

PMCPMC13408529

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.